GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates

GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update

GenSight Biologics Launches Newsletter for Retail Investors

GenSight Biologics Appoints William Monteith to its Board of Directors

GenSight Biologics announces a successful offering for an amount over €9.2 million

GenSight Biologics Announces the Filing of its 2023 Universal Registration Document

GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update

GenSight Biologics Announces Its 2024 Financial Calendar

GenSight Biologics Reports Full Year 2023 Consolidated Financial Results

GenSight Biologics announces completion of a €5 million capital increase with Sofinnova Partners, Invus, UPMC Enterprises and Heights Capital